Modulation of hippocampal norepinephrine release by cholinergic agonists is altered by AF64A lesion

[1]  P. Potter,et al.  Lesion with the neurotoxin AF64A alters hippocampal cholinergic receptor function , 1995, Brain Research Bulletin.

[2]  A. Lajtha,et al.  Neurochemical Evidence of Heterogeneity of Presynaptic and Somatodendritic Nicotinic Acetylcholine Receptors a , 1995, Annals of the New York Academy of Sciences.

[3]  Hoau Yan Wang,et al.  Receptor-mediated activation of G proteins is reduced in postmortem brains from Alzheimer's disease patients , 1994, Neuroscience Letters.

[4]  L. F. Kromer,et al.  Cholinergic Deafferentation of Dorsal Hippocampus by Fimbria‐Fornix Lesioning Differentially Regulates Subtypes (m1‐m5) of Muscarinic Receptors , 1994, Journal of neurochemistry.

[5]  E. Vizi,et al.  Release of Acetylcholine and Noradrenaline from the Cholinergic and Adrenergic Afferents in Rat Hippocampal CA1, CA3 and Dentate Gyrus Regions , 1994, The European journal of neuroscience.

[6]  P. Potter,et al.  Alterations in modulation of acetylcholine release following lesion of hippocampal cholinergic neurons with the neurotoxin AF64A , 1993, Neuropharmacology.

[7]  K. Zilles,et al.  Muscarinic desensitization after septal lesions in rat hippocampus: Evidence for the involvement of G-proteins , 1992, Neuroscience.

[8]  S. Gauthier,et al.  Comparative Alterations of Nicotinic and Muscarinic Binding Sites in Alzheimer's and Parkinson's Diseases , 1992, Journal of neurochemistry.

[9]  D. Mash,et al.  Loss of high‐affinity agonist binding to M1 muscarinic receptors in Alzheimer's disease: Implications for the failure of cholinergic replacement therapies , 1991, Annals of neurology.

[10]  S. Wonnacott,et al.  Isolation of Hippocampal Synaptosomes on Percoll Gradients: Cholinergic Markers and Ligand Binding Sites , 1991, Journal of neurochemistry.

[11]  V. Dawson,et al.  Hippocampal muscarinic supersensitivity after AF64A medial septal lesion excludes M1 receptors , 1990, Brain Research Bulletin.

[12]  R. Cowburn,et al.  Alzheimer's disease: is there a problem beyond recognition? , 1990, Trends in pharmacological sciences.

[13]  L. Potter,et al.  Affinities of different cholinergic agonists for the high and low affinity states of hippocampal M1 muscarine receptors. , 1989, The Journal of pharmacology and experimental therapeutics.

[14]  R. Ransom,et al.  NMDA-induced hippocampal [3H]norepinephrine release is modulated by glycine. , 1988, European journal of pharmacology.

[15]  W. Millard,et al.  Induction of cortical cholinergic hypofunction and memory retention deficits through intracortical AF64A infusions , 1988, Brain Research.

[16]  E. Vizi,et al.  Selective impairment of acetylcholine release and content in the central nervous system following intracerebroventricular administration of ethylcholine mustard aziridinium ion (AF64A) in the rat , 1986, Neurochemistry International.

[17]  D. Mash,et al.  Characterization of l‐[3H]Nicotine Binding in Human Cerebral Cortex: Comparison Between Alzheimer's Disease and the Normal , 1986, Journal of neurochemistry.

[18]  E. Perry,et al.  Cholinergic Receptors in Cognitive Disorders , 1986, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[19]  J. Říčný,et al.  Effect of 2‐(4‐Phenylpiperidino)cyclohexanol on Acetylcholine Release and Subcellular Distribution in Rat Striatal Slices , 1986, Journal of neurochemistry.

[20]  B. Winblad,et al.  Muscarinic receptor subtypes in hippocampus in Alzheimer's disease and mixed dementia type , 1986, Neuroscience Letters.

[21]  H. Yamamura,et al.  Regional differences in ethylcholine mustard aziridinium ion (AF64A)-induced deficits in presynaptic cholinergic markers for the rat central nervous system. , 1985, The Journal of pharmacology and experimental therapeutics.

[22]  D. Mash,et al.  Loss of M2 muscarine receptors in the cerebral cortex in Alzheimer's disease and experimental cholinergic denervation. , 1985, Science.

[23]  D. McKeag,et al.  Intracerebroventricular administration of ethylcholine mustard aziridinium ion (AF64A) reduces release of acetylcholine from rat hippocampal slices , 1985, Neuropharmacology.

[24]  T. J. Walsh,et al.  AF64A, a cholinergic neurotoxin, selectively depletes acetylcholine in hippocampus and cortex, and produces long-term passive avoidance and radial-arm maze deficits in the rat , 1984, Brain Research.

[25]  L. Jarrard,et al.  Behavioral and neurochemical effects of intraventricular AF64A administration in rats , 1984, Pharmacology Biochemistry and Behavior.

[26]  D L Price,et al.  Alzheimer's disease: a disorder of cortical cholinergic innervation. , 1983, Science.

[27]  R. Hammer,et al.  Muscarinic receptor subtypes: M1 and M2 biochemical and functional characterization. , 1982, Life sciences.

[28]  R. Bartus,et al.  The cholinergic hypothesis of geriatric memory dysfunction. , 1982, Science.

[29]  D. Abraham,et al.  Long-term central cholinergic hypofunction induced in mice by ethylcholine aziridinium ion (AF64A) in vivo. , 1982, The Journal of pharmacology and experimental therapeutics.

[30]  A. Fisher,et al.  The AF64a-treated mouse: possible model for central cholinergic hypofunction. , 1981, Science.

[31]  Peter Davies,et al.  Regional distribution of muscarinic acetylcholine receptor in normal and Alzheimer's-type dementia brains , 1977, Brain Research.

[32]  F. Fonnum,et al.  A rapid radiochemical method for the determination of choline acetyltransferase , 1975, Journal of neurochemistry.

[33]  Oliver H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[34]  L. Snell,et al.  Effects of nicotinic agonists and antagonists on N‐methyl‐D‐aspartate‐induced 3H‐norepinephrine release and 3H‐(1‐[1‐(2‐thienyl)cyclohexyl]‐piperidine) binding in rat hippocampus , 1989, Synapse.

[35]  H. Bourne.  GTP-binding proteins: One molecular machine can transduce diverse signals , 1986, Nature.